Literature DB >> 22406302

Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD.

Loes E M Kistemaker1, Tjitske A Oenema, Herman Meurs, Reinoud Gosens.   

Abstract

Acetylcholine is the primary parasympathetic neurotransmitter in the airways and an autocrine/paracrine secreted hormone from non-neuronal origins including inflammatory cells and airway structural cells. In addition to the well-known functions of acetylcholine in regulating bronchoconstriction and mucus secretion, it is increasingly evident that acetylcholine regulates inflammatory cell chemotaxis and activation, and also participates in signaling events leading to chronic airway wall remodeling that is associated with chronic obstructive airway diseases including asthma and COPD. As muscarinic receptors appear responsible for most of the pro-inflammatory and remodeling effects of acetylcholine, these findings have significant implications for anticholinergic therapy in asthma and COPD, which is selective for muscarinic receptors. Here, the regulatory role of acetylcholine in inflammation and remodeling in asthma and COPD will be discussed including the perspectives that these findings offer for anticholinergic therapy in these diseases.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406302     DOI: 10.1016/j.lfs.2012.02.021

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  29 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  Airway Innervation and Plasticity in Asthma.

Authors:  L E M Kistemaker; Y S Prakash
Journal:  Physiology (Bethesda)       Date:  2019-07-01

Review 3.  Anticholinergics/antimuscarinic drugs in asthma.

Authors:  Xavier Soler; Joe Ramsdell
Journal:  Curr Allergy Asthma Rep       Date:  2014-12       Impact factor: 4.806

4.  Muscarinic M3 receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in mice.

Authors:  Loes E M Kistemaker; Ronald P van Os; Albertina Dethmers-Ausema; I Sophie T Bos; Machteld N Hylkema; Maarten van den Berge; Pieter S Hiemstra; Jürgen Wess; Herman Meurs; Huib A M Kerstjens; Reinoud Gosens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-07       Impact factor: 5.464

Review 5.  Airway and lung remodelling in chronic pulmonary obstructive disease: a role for muscarinic receptor antagonists?

Authors:  Michael Roth
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

Review 6.  Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.

Authors:  Khuder Alagha; Alain Palot; Tunde Sofalvi; Laurie Pahus; Marion Gouitaa; Celine Tummino; Stephanie Martinez; Denis Charpin; Arnaud Bourdin; Pascal Chanez
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

Review 7.  Emerging role of long acting muscarinic antagonists for asthma.

Authors:  Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 8.  Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway.

Authors:  Tonio Pera; Raymond B Penn
Journal:  Curr Opin Pharmacol       Date:  2014-04-17       Impact factor: 5.547

Review 9.  Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions.

Authors:  Adeeb Bulkhi; Farnaz Tabatabaian; Thomas B Casale
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 10.  Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?

Authors:  G P Currie; B J Lipworth
Journal:  QJM       Date:  2015-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.